SHIELD THERAPEUTICS PLC ORD 1.5P chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.01
Dividend & YieldN/A£ (N/A)
Beta 1.34
Market capitalization 20.92M
Operating cash flow -17.46M
ESG Scores unknown

Company description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -953k 999k -2.08M 1.64M
Total Cashflows From Investing Activities -3.29M -1.37M -20k -2.05M
Net Borrowings -336k -176k -48k -76k
Total Cash From Financing Activities -379k -203k -47k 27.58M
Change To Operating Activities 139k -288k 148k -515k
Issuance Of Stock 26k 26k 6k 27.7M
Net Income -1.79M -8.8M -2.63M -19.34M
Change In Cash -3.52M -5.63M -1.2M 9.18M
Effect Of Exchange Rate 266k 266k 266k 382k
Total Cash From Operating Activities 151k -4.07M -1.4M -16.74M
Depreciation 2.26M 2.29M 2.18M 1.62M
Change To Account Receivables 541k 681k -264k -2.88M
Other Cashflows From Financing Activities -43k -53k -5k -45k
Change To Netincome -490k 1.56M 1.15M 2.4M
Capital Expenditures -372k -372k -372k -372k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 4.3M 2.5M 2.58M 579k
Income Before Tax -5.15M -9.07M -1.89M -19.57M
Net Income -1.79M -8.8M -2.63M -19.34M
Selling General Administrative 12.43M 6.77M 8.61M 20.02M
Gross Profit 11.57M 234k 9.03M 539k
Ebit -5.16M -9.04M -2.15M -19.95M
Operating Income -5.16M -9.04M -2.15M -19.95M
Interest Expense -29k -1k -1k
Income Tax Expense -3.36M -266k 744k -229k
Total Revenue 11.88M 719k 10.39M 1.52M
Cost Of Revenue 311k 485k 1.35M 980k
Total Other Income ExpenseNet 8k -31k 268k 387k
Net Income From Continuing Ops -1.79M -8.8M -2.63M -19.34M
Net Income Applicable To Common Shares -1.79M -8.8M -2.63M -19.34M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 3.1M 4.17M 2.25M 3.38M
Total Stockholder Equity 40.43M 32.15M 30.28M 41.03M
Other Current Liabilities 403k 607k 753k 110k
Total Assets 43.53M 36.32M 32.53M 44.41M
Common Stock 1.75M 1.76M 1.76M 3.24M
Other Current Assets
Retained Earnings -78.05M -86.39M -88.25M -106.59M
Treasury Stock 28.39M 28.43M 28.41M 29.81M
Cash 9.78M 4.14M 2.94M 12.12M
Total Current Liabilities 3.1M 4.17M 2.25M 3.38M
Other Stockholder Equity 28.39M 28.43M 28.41M 29.81M
Property, Plant, and Equipment 155k 26k 32k 304k
Total Current Assets 12.42M 6.39M 5.23M 17.26M
Net Tangible Assets 17.41M 11.21M 11.44M 23.71M
Net Receivables 1.96M 1.15M 656k 1.77M
Accounts Payable 22k 2.67M 395k 1.31M


Insider Transactions

Here are the insider transactions of stock shares related to SHIELD THERAPEUTICS PLC ORD 1.5P:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Jupiter Asset Management LtdD2022-08-3140.4k
AOP Orphan International AGD2022-08-08
Jupiter Asset Management LtdD2022-08-08
W. Health L.P.D2022-08-08
W. Health L.P.D2022-08-05
AOP Orphan International AGD2022-08-0541.2M
AOP Orphan International AGD2022-06-21
W. Health L.P.D2022-06-21
Schweiger (Christian)D2021-12-31
Hasler (Hans Peter)D2021-12-31
Llewellyn-Davies (Peter)D2021-12-31
Watts (Timothy William)D2021-12-31
Lundstrom (Anders)Bought at price 0.61 per share.D2021-08-2010k
AOP Orphan International AGD2021-06-11
Jupiter Asset Management LtdD2021-06-11
Sterling Investments Management LtdD2021-06-11
W. Health L.P.D2021-06-11
W. Health L.P.D2021-04-28
AOP Orphan International AGD2021-04-28
Jupiter Asset Management LtdD2021-04-28
AOP Orphan International AGD2021-03-1915.8M
Jupiter Asset Management LtdD2021-03-197.99M
Schweiger (Christian)Bought at price 0.42 per share.D2021-03-191.3M
Schweiger (Christian)D2021-03-19262.7k
Universities Superannuation Scheme Ltd (Uss)D2021-03-19340k
W. Health L.P.D2021-03-197.64k
Watts (Timothy William)Bought at price 0.42 per share.D2021-03-191M
Universities Superannuation Scheme Ltd (Uss)D2021-03-12311.13k
Hasler (Hans Peter)Bought at price 0.53 per share.D2021-03-05200k
Hasler (Hans Peter)Bought at price 0.52 per share.D2021-03-03200k
Hasler (Hans Peter)Bought at price 0.81 per share.D2021-01-20100k
Watts (Timothy William)Bought at price 0.82 per share.D2021-01-19100k
Watts (Timothy William)D2020-12-31
Schweiger (Christian)D2020-12-31
Sterritt (Carl Andrew)D2020-12-31
Llewellyn-Davies (Peter)D2020-12-31
Sterritt (Carl Andrew)D2020-12-164.72M
Watts (Timothy William)Bought at price 0.93 per share.D2020-12-11100k
Sterritt (Carl Andrew)D2020-11-251.99M

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to SHIELD THERAPEUTICS PLC ORD 1.5P. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on SHIELD THERAPEUTICS PLC ORD 1.5P

Here is the result of two systematic investment strategies applied to SHIELD THERAPEUTICS PLC ORD 1.5P. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows the equity curve of the two systematic investment strategies applied to SHIELD THERAPEUTICS PLC ORD 1.5P:

SHIELD THERAPEUTICS PLC ORD 1.5P automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -28.97% on the backtest period.

Performance at glance

Performance

-28.97 %

Latent gain

-565.75 £

Invested capital

1952.75 £

Annualized return

-7.03 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on SHIELD THERAPEUTICS PLC ORD 1.5P

This is the result of two momentum investment strategies applied to SHIELD THERAPEUTICS PLC ORD 1.5P. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows all the entries opened by the momentum investment system on SHIELD THERAPEUTICS PLC ORD 1.5P:

SHIELD THERAPEUTICS PLC ORD 1.5P momentum entries
  • The first momentum investment strategy would give -12.62% of return on SHIELD THERAPEUTICS PLC ORD 1.5P. That represents -458.67£ of latent gain with 3634.17£ of employed capital.
  • The second momentum investment strategy would give -11.28% of return on SHIELD THERAPEUTICS PLC ORD 1.5P. That represents -194.94£ of latent gain with 1727.94£ of employed capital.
Performance at glance (1Q Momentum)

Performance

-12.62 %

Latent gain

-458.67 £

Invested capital

3634.17 £

Annualized return

-20.94 %
Performance at glance (2Q Momentum)

Performance

-11.28 %

Latent gain

-194.94 £

Invested capital

1727.94 £

Annualized return

-3.1 %

Momentum equity curve on SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows the equity curve of the two momentum strategies applied to SHIELD THERAPEUTICS PLC ORD 1.5P:

SHIELD THERAPEUTICS PLC ORD 1.5P momentum equity

Note: the dividends potentially given by SHIELD THERAPEUTICS PLC ORD 1.5P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows the employed capital evolution of the two momentum strategies on SHIELD THERAPEUTICS PLC ORD 1.5P since the beginning:

SHIELD THERAPEUTICS PLC ORD 1.5P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on SHIELD THERAPEUTICS PLC ORD 1.5P

Buy the dip entry openings on SHIELD THERAPEUTICS PLC ORD 1.5P

SHIELD THERAPEUTICS PLC ORD 1.5P

The performance achieved by the robo-advisor on SHIELD THERAPEUTICS PLC ORD 1.5P is -44.39%. That represents -116.52$ of latent gain with 262.52£ of employed capital. The following chart shows SHIELD THERAPEUTICS PLC ORD 1.5P stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of SHIELD THERAPEUTICS PLC ORD 1.5P, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-44.39 %

Latent gain

-116.52 £

Invested capital

262.52 £

Annualized return

-20.94 %

Equity curve of the strategy applied to SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows the result of the investment strategy applied to SHIELD THERAPEUTICS PLC ORD 1.5P:

SHIELD THERAPEUTICS PLC ORD 1.5P

Note: the dividends potentially given by SHIELD THERAPEUTICS PLC ORD 1.5P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows the employed capital evolution since the beginning of the investment strategy on SHIELD THERAPEUTICS PLC ORD 1.5P:

SHIELD THERAPEUTICS PLC ORD 1.5P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on SHIELD THERAPEUTICS PLC ORD 1.5P

In this section, I will compare the three previous investment strategies applied to SHIELD THERAPEUTICS PLC ORD 1.5P.

Equity curve comparison on SHIELD THERAPEUTICS PLC ORD 1.5P

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

SHIELD THERAPEUTICS PLC ORD 1.5P investment strategy comparison

Employed capital comparison on SHIELD THERAPEUTICS PLC ORD 1.5P

SHIELD THERAPEUTICS PLC ORD 1.5P investment comparison

Performance comparison on SHIELD THERAPEUTICS PLC ORD 1.5P

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -28.97% -565.75£ 1952.75£ -7.03%
Momentum 1 quarter -12.62% -458.67£ 3634.17£ -3.25%
Momentum 2 quarters -11.28% -194.94£ 1727.94£ -3.1%
Non-directional -44.39% -116.52£ 262.52£ -20.94%
Annualized return comparison

Automatic investment

-7.03 %

Momentum 1Q

-3.1 %

Momentum 2Q

-3.1 %

Non-directional

-20.94 %

Correlated stocks

Here are the most positively and negatively correlated stocks with SHIELD THERAPEUTICS PLC ORD 1.5P:

Positive correlations

Most correlated stocks this year

  • SHIELD THERAPEUTICS PLC ORD 1.5P

  • Most correlated stocks last 3 months

  • SHIELD THERAPEUTICS PLC ORD 1.5P
  • Devon Energy Corp
  • MeiraGTx Holdings plc
  • Medigus Ltd
  • Fortress Biotech Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • BIOSYNEX

  • Note: The algorithm computes the probability of correlation between SHIELD THERAPEUTICS PLC ORD 1.5P and the other stocks. There may be false positives or some missing correlated stocks. If the price of SHIELD THERAPEUTICS PLC ORD 1.5P does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name SHIELD THERAPEUTICS PLC ORD 1.5P
    Country United Kingdom
    City Gateshead
    Address Northern Design Centre
    Phone 44 1915 118 500
    Website www.shieldtherapeutics.com
    FullTime employees 15
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XLON
    Ticker STX.XLON
    Market www.londonstockexchange.com

    SHIELD THERAPEUTICS PLC ORD 1.5P ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown